secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001790340-25-000014
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports 50% ORR in Phase 2a of IMM-1-104/mFFX; raises $13.7M via ATM
--------------------------------------------------------------------------------

- As of Jan 6, 2025, 3 of 6 evaluable patients achieved partial response, 3 stable disease; 50% ORR per RECIST.
- IMM-1-104 with mFFX generally well tolerated; 3 partial responders and 1 stable disease patient remain on treatment.
- Raised net proceeds of $13.7M in January 2025 through at-the-market equity offering program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000014/0001790340-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000014/imrx-20250113.htm
  HTML page:      https://secwatch.observer/filing/0001790340-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer